RenovoRx’s Clinical Data Abstract to be Showcased at SIR 2026
RenovoRx, Inc., a company specializing in targeted oncology therapies, has announced the acceptance of a clinical data abstract at the forthcoming 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting in Toronto, Canada. This abstract highlights findings on the use of the Trans-Arterial Micro-Perfusion (TAMP) therapy platform for treating locally advanced pancreatic cancer (LAPC).
The abstract, entitled "What PET/CT Reveals After Transarterial Microperfusion for Pancreatic Cancer," is set for presentation by Dr. Mustafa Al-Roubaie from Moffitt Cancer Center, scheduled for April 13, 2026. It is part of a collaborative effort by a team of cancer specialists, examining the metabolic responses observed when employing RenovoRx’s TAMP platform for localized chemotherapeutic delivery.
LAPC presents treatment challenges, largely due to the tumor's dense, hypovascular stroma, which often limits the effectiveness of conventional systemic chemotherapy. RenovoRx’s TAMP platform aims to address this issue by delivering chemotherapy directly to the tumor site using their patented RenovoCath device. This approach potentially improves drug delivery efficacy while reducing systemic toxicity.
Dr. Al-Roubaie notes, "Patients with LAPC have a difficult prognosis, partly due to the stroma's nature which impedes systemic chemotherapy. Regional intra-arterial therapeutic delivery, as facilitated by the TAMP platform, aims to overcome this barrier."
RenovoCath Device Overview
The RenovoCath device, cleared by the FDA, is designed for isolating blood flow and delivering therapeutic agents to specific areas within the peripheral vascular system. It is used for various purposes, including arteriography, preoperative vessel occlusion, and chemotherapy drug infusion.
Commercialization and Future Prospects
RenovoRx has been actively marketing its RenovoCath device, having reported revenue generation from sales in 2025. With demand anticipated to rise, the company is exploring further commercialization opportunities, potentially in collaboration with medical device partners. The device is currently utilized in the Phase III TIGeR-PaC trial, evaluating its effectiveness in delivering gemcitabine for pancreatic cancer treatment under an investigational new drug application regulated by the FDA.
In addition to being cleared for the RenovoCath device, the drug-device combination involving intra-arterial gemcitabine has received Orphan Drug Designation for pancreatic and bile duct cancers. This status could provide the product with market exclusivity upon FDA approval.
RenovoRx is committed to transforming cancer treatment by providing innovative solutions for precise therapeutic delivery. Although the RenovoCath and the combination product are not yet approved for commercial sale, the ongoing trials and scientific presentations like the upcoming SIR meeting exemplify the company's dedication to advancing cancer care.